News
Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...
18m
Hartlepool Mail on MSNNorth East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adultsIn a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, ...
The goal with ProKidney's rilparencel-branded therapy is “to demonstrate the therapy’s potential to preserve kidney function in patients with advanced chronic kidney disease and diabetes.” ...
A recent study led by Paul DeCaen, Ph.D., associate professor of Pharmacology, has identified novel molecular mechanisms by ...
9d
Philstar.com on MSNChronic kidney disease: A health crisis we should no longer ignoreWhen was the last time you had your blood sugar and blood pressure checked? If you’re a smoker, a drinker, are overweight, ...
New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...
Explore more
Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...
Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, ...
Type 2 diabetes is on the rise, and with it, associated complications, like diabetic kidney disease (DKD). Diabetic kidney ...
The goal with ProKidney Corp.'s rilparencel-branded therapy is "to demonstrate the therapy's potential to preserve kidney ...
Shares of ProKidney rose in early trading after it received FDA support for its path to accelerated approval of its rilparencel kidney disease drug. The stock was up 5.4% to $3.89 Tuesday and has more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results